SCHEMBL4579294

SCHEMBL4579294

COc1cc(Nc2ncnc3cc(F)c([N+](=O)[O-])cc23)c(OC)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.57
SRC P12931 2/20 0.57
RIPK2 O43353 1/20 0.57
NOD1 Q9Y239 1/20 0.57
ABCG2 Q9UNQ0 3/20 0.57
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
HTT P42858 1/20 0.52
KDR P35968 5/20 0.51
FLT1 P17948 3/20 0.51
FLT4 P35916 2/20 0.51
FGFR1 P11362 2/20 0.51
EPHB2 P29323 1/20 0.51
EPHB4 P54760 2/20 0.49
EPHA2 P29317 1/20 0.49
AURKA O14965 1/20 0.48
ERBB2 P04626 1/20 0.48
INSR P06213 1/20 0.48
FBP1 P09467 1/20 0.48
PDGFRB P09619 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4579422 0.95 EGFR (0.63) EGFRSRCRIPK2NOD1ABCG2
SCHEMBL4577846 0.95 EGFR (0.65) EGFRSRCRIPK2NOD1ABCG2
SCHEMBL4578447 0.85 EGFR (0.55) EGFRSRCRIPK2NOD1ABCG2
SCHEMBL30820491 0.83 EGFR (0.63) EGFRABCG2ALDH1A1MAPTHTT
SCHEMBL4578209 0.83 EGFR (0.58) EGFRSRCRIPK2NOD1ABCG2
SCHEMBL3239502 0.82 EGFR (0.59) EGFRABCG2KDRFLT1FLT4
SCHEMBL4578880 0.82 EGFR (0.53) EGFRSRCRIPK2NOD1ABCG2
SCHEMBL4578322 0.81 EGFR (0.62) EGFRSRCRIPK2NOD1ABCG2
SCHEMBL4577834 0.80 SRC (0.56) EGFRSRCABCG2KDRFLT1
SCHEMBL4579090 0.80 EGFR (0.59) EGFRSRCRIPK2NOD1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846699-B2 Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof HANMI PHARM. CO., LTD. (KR) 2014-09-30 US disclosed
EP-1951686-B1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM IND CO LTD (KR) 2013-04-03 EP disclosed
CN-101304978-B Quinazoline derivative as multi-component inhibitor, pharmaceutical composition and application HANMI PHARM IND CO LTD 2012-12-26 CN disclosed
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof HANMI PHARM. CO., LTD (KR) 2008-12-25 US disclosed
CN-101304978-A Quinazoline derivatives as multiplex inhibitors and process for their preparation HANMI PHARM IND CO LTD (KR) 2008-11-12 CN disclosed
EP-1951686-A1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2008-08-06 EP disclosed
WO-2007055514-A1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof ABL1, JAK1, BTK EGFR 955/4885SRC 82/4885RIPK2 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.